In celebration of International Women's Day, we present this series of table talks on topics of Diversity, Equity, and Inclusion. Join one or more of these small group events for an intimate discussion on current event topics with leaders across different organizations.
Challenging the status quo is a mindset shift which you can bring about by being conscious about how things operate today – and by proposing a new and better way of doing things. Join P.K., Vice President of Global Development at Amgen in a fascinating discussion on choosing to challenge the status quo.
P.K. earned her Medical Degree at the University of Texas Medical School at Houston, where she was a member of the Alpha Omega Alpha (AOA) Honor Medical Society. Subsequently, she completed her Internal Medicine Residency at Baylor College of Medicine and Hematology/Oncology Fellowship at the University of Texas MD Anderson Cancer Center, where she also served as a Chief Fellow. During her fellowship, she was named Fellow of the Year and earned the ASCO Young Investigator Award for her translational research in angiogenesis.
Prior to joining Amgen, P.K. was an Assistant Professor, Department of Breast Medical Oncology, at the University of Texas MD Anderson Cancer Center. She co-led the development of the first multidisciplinary breast cancer survivorship clinic at MD Anderson and served as the principal investigator of multiple drug studies.
From 2013 through 2015, as the Neupogen® /Neulasta® Global Development Lead and US Medical Lead, P.K. led a cross-functional team in the development and registration of the Neulasta® Onpro™. In addition, she led a pre-clinical and clinical team in the successful submission of the Neupogen® and Neulasta® Acute Radiation Syndrome (ARS) sBLAs, leading to approval of both products for the ARS indication.
From 2014 to 2017, P.K. served as the Therapeutic Area Head for Oncology in the U.S. Medical Organization, where she oversaw U.S. oncology research activities, launch activities for newly approved oncology molecules, medical advocacy efforts, extramural research, and independent medical education grants. During this time, she successfully led the medical launch activities for IMLYGIC®, Kyprolis®, Neulasta Onpro™, and Blincyto®. In addition, P.K. served as the Global Product General Manager for three early-stage oncology molecules focused upon MCL-1 and KRAS G12C. Furthermore, P.K. was appointed by the FDA to be the industry representative to the Oncology Drug Advisory Committee (ODAC) for a four-year term, ending in 2019.
In April 2019, P.K. became Vice President of Global Development and Therapeutic Area Head of Hematology, where she is responsible for guiding and accelerating late development activities addressing both marketed hematology programs (Blincyto and Kyprolis) and guiding the late development of programs that focus upon BCMA, FLT3, CD33, and MCL-1.
Event is open to: HBA Members only